- Home
- EWCZ vs PRQR Comparison
EWCZ vs PRQR Comparison
Compare EWCZ & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- PRQR
- Stock Information
- Founded
- EWCZ 2004
- PRQR 2012
- Country
- EWCZ United States
- PRQR Netherlands
- Employees
- EWCZ N/A
- PRQR N/A
- Industry
- EWCZ Package Goods/Cosmetics
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- PRQR Health Care
- Exchange
- EWCZ Nasdaq
- PRQR Nasdaq
- Market Cap
- EWCZ 239.2M
- PRQR 232.8M
- IPO Year
- EWCZ 2021
- PRQR 2014
- Fundamental
- Price
- EWCZ $3.92
- PRQR $1.99
- Analyst Decision
- EWCZ Hold
- PRQR Strong Buy
- Analyst Count
- EWCZ 6
- PRQR 8
- Target Price
- EWCZ $5.50
- PRQR $8.88
- AVG Volume (30 Days)
- EWCZ 387.3K
- PRQR 378.7K
- Earning Date
- EWCZ 11-13-2025
- PRQR 11-06-2025
- Dividend Yield
- EWCZ N/A
- PRQR N/A
- EPS Growth
- EWCZ N/A
- PRQR N/A
- EPS
- EWCZ 0.20
- PRQR N/A
- Revenue
- EWCZ $212,509,000.00
- PRQR $20,129,184.00
- Revenue This Year
- EWCZ N/A
- PRQR N/A
- Revenue Next Year
- EWCZ $2.37
- PRQR N/A
- P/E Ratio
- EWCZ $19.65
- PRQR N/A
- Revenue Growth
- EWCZ N/A
- PRQR 8.65
- 52 Week Low
- EWCZ $2.72
- PRQR $1.07
- 52 Week High
- EWCZ $8.91
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- EWCZ 37.66
- PRQR 37.36
- Support Level
- EWCZ $3.59
- PRQR $2.21
- Resistance Level
- EWCZ $3.96
- PRQR $2.50
- Average True Range (ATR)
- EWCZ 0.21
- PRQR 0.15
- MACD
- EWCZ -0.03
- PRQR -0.03
- Stochastic Oscillator
- EWCZ 30.41
- PRQR 4.63
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.